Screener
Asset Entities ASST Medical Device — Transaction costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Asset Entities in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.
The source filing: Asset Entities’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054985
| Line item | Successor / Three Months Ended June 30, 2026 | Predecessor / Three Months Ended June 30, 2025 |
|---|---|---|
| Interest expense on long-term notes payable, at fair value | (40) | — |
| Change in fair value on long-term notes payable, at fair value | (299) | — |
| Gain on extinguishment of debt | 30 | — |
| Transaction costs | — | (5,437) |
| Total other income/(expense) | 646 | (5,185) |
| Net loss before income taxes | (257,603) | (8,875) |
| Income tax benefit/(expense) | — | — |
| Net loss | $(257,603) | $(8,875) |
Item 1. Consolidated Financial Statements
FAQ
- What is Asset Entities's medical device — transaction costs?
- Asset Entities (ASST) reported medical device — transaction costs of $0 in Q2 2026.
- What does medical device — transaction costs mean?
- Includes the direct costs associated with completing specific business transactions, such as acquisitions or financing activities, within the medical device segment. Tracking these costs is essential for understanding the efficiency of capital deployment and inorganic growth strategies.
Ask your AI about Asset Entities's medical device — transaction costs.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude